RESEARCHER PROFILE

Henry G. Beetham

← Back to Victorian Centre for Functional Genomics

H

Victorian Centre for Functional Genomics

Protein Kinase Regulation and GTPase SignalingCell Adhesion Molecules ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment StudiesCancer Cells and Metastasis

Henry G. Beetham works in Protein Kinase Regulation and GTPase Signaling, Cell Adhesion Molecules Research, PI3K/AKT/mTOR signaling in cancer, Breast Cancer Treatment Studies, Cancer Cells and Metastasis. Recorded institutional associations include Peter MacCallum Cancer Centre, Victorian Centre for Functional Genomics.

69Publications
390Citations
7H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition

    2014 · 141 citations

  2. A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation

    2015 · 78 citations

  3. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

    2021 · 52 citations

  4. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells

    2015 · 34 citations

  5. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function

    2018 · 32 citations

  6. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

    2021 · 19 citations

  7. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells

    2019 · 13 citations

  8. Involvement of Kindlin-1 in cutaneous squamous cell carcinoma

    2024 · 6 citations

  9. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer

    2021 · 5 citations

  10. A semi-automated pipeline for quantifying drusen-like deposits in human induced pluripotent stem cell-derived retinal pigment epithelium cells

    2023 · 4 citations

  11. Genome-wide analysis of host-encoded microRNAs modulating SARS-CoV-2 infection

    2025 · 2 citations

  12. High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma

    2025 · 2 citations

  13. Abstract B41: Statins show synthetic lethality in E-cadherin-deficient cells and are synergistic with SRC and HDAC inhibitors

    2017 · 1 citations

  14. Mechanisms of Hereditary Diffuse Gastric Cancer Initiation: The role of E-cadherin in the Epithelial-Mesenchymal Transition

    2012 · 0 citations

  15. Abstract 3814: Synthetic lethal approaches targeting E-cadherin-deficient cancers

    2016 · 0 citations

  16. Abstract B04: Synthetic lethal targeting of E-cadherin-deficient cancers

    2017 · 0 citations

  17. A Synthetic Lethal Approach to the Development of Novel Cancer Therapies

    2018 · 0 citations

  18. Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

    2023 · 0 citations

  19. Data from Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

    2023 · 0 citations

  20. Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

    2023 · 0 citations

  21. Supplementary Data from Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

    2023 · 0 citations

  22. Supplementary Data from Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

    2023 · 0 citations

  23. Supplementary Data from Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

    2023 · 0 citations

  24. Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

    2023 · 0 citations

  25. Supplementary Data from Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

    2023 · 0 citations

← Return to the university profile